Advertisement

Topics

Protalex Doses First Patient in Fourth Cohort of European Phase 1b Study of PRTX-100 in ITP

09:00 EST 13 Nov 2017 | Businesswire

This article has expired, however you can still download the PDF.
Preview:
Protalex, Inc. (OTCQB:PRTX), a clinical-stage biopharmaceutical company, today announced that following a planned interim analysis of data from the third dose cohort of its European Phase 1b study of PRTX-100, the Company’s hi...

Other Sources for this Article

LHA
Anne Marie Fields, 212-838-3777
afields@lhai.com

NEXT ARTICLE

More From BioPortfolio on "Protalex Doses First Patient in Fourth Cohort of European Phase 1b Study of PRTX-100 in ITP"

Advertisement
Quick Search
Advertisement
Advertisement

 

Relevant Topic

Biopharmaceuticals
Biopharmaceuticals are medical drugs produced using biotechnology. They include proteins (including antibodies), nucleic acids (DNA, RNA or antisense oligonucleotides) and living microorganisms like virus and bacteria where the virulance of viruses and b...